Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LILAC-2: Trofinetide Open-Label Extension for Rett Syndrome
NCT04776746Phase 3Terminated
- Sponsor
- Acadia Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Jun 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trofinetide in Rett syndrome (RTT), sponsored by Acadia Pharmaceuticals. Started Nov 2020; status: terminated.
02
Drugs
trofinetide
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT04776746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776746.